In Conversation

Spain Pharma Report September 2019
Latest Reports
Spain Pharma Report September 2019
- 2019
Building on the topics covered in our March 2019 report, this latest edition of Healthcare & Life Sciences Review Spain takes a closer look at the broader Spanish life sciences value chain. With the Iberian nation enjoying an economic rebound, pharmaceutical multinationals are once again seeing Spain as a favourable investment destination, taking into account the country’s Swiss or German quality levels at southern European prices. Indeed, recent years have seen big ticket infrastructural investments in Spanish manufacturing plants from the likes of Pfizer, Takeda and Bayer. This trend is also prevalent in the medical devices sphere, with Becton…
Spain Pharma Report March 2019
Latest Reports
Spain Pharma Report March 2019
- 2019
Having largely recovered from the impact of the global financial crisis and with several impressive fundamentals in place, Spain once again stands as one of Europe’s premier healthcare and life science investment destinations. These fundamentals include a revamped market access process, a high-quality yet affordable manufacturing base, and a budding reputation as one of the best clinical trials destinations on the continent.   Other topics touched on in this report include Spain’s booming biotech scene, the internationalization efforts of the country’s well-established mid-cap firms, a private healthcare market growing in both size and importance, and the nation’s expertise in…
Spain Pharma Report
Latest Reports
Spain Pharma Report
- 2014
Spain Pharma Report
Latest Reports
Spain Pharma Report
- 2008
We use cookies to ensure that we give you the best experience on our site. For more info click here